Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 21, Number 9—September 2015
THEME ISSUE
Emerging Infections Program

Emerging Infections Program

Incidence of Clinician-Diagnosed Lyme Disease, United States, 2005–2010

Christina A. NelsonComments to Author , Shubhayu Saha, Kiersten J. Kugeler, Mark J. Delorey, Manjunath B. Shankar, Alison Hinckley, and Paul S. Mead
Author affiliations: Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (C.A. Nelson, K.J. Kugeler, M.J. Delorey, A.F. Hinckley, P.S. Mead); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S. Saha, M.B. Shankar)

Main Article

Figure 2

Trends of annual incidence of Lyme disease in MarketScan compared with trends in incidence from US surveillance, 2005–2010. Incidence is per 100,000 persons. Trends in interannual incidence fluctuation did not differ significantly between MarketScan and US surveillance (χ2 test, p = 0.81). *Cases reported through the National Notifiable Diseases Surveillance System. During 2005–2007, incidence was calculated as the number of confirmed cases/100,000 persons; during 2008–2010, incidence was calcul

Figure 2. Trends of annual incidence of Lyme disease in MarketScan compared with trends in incidence from US surveillance, 2005–2010. Incidence is per 100,000 persons. Trends in interannual incidence fluctuation did not differ significantly between MarketScan and US surveillance (χ2 test, p = 0.81). *Cases reported through the National Notifiable Diseases Surveillance System. During 2005–2007, incidence was calculated as the number of confirmed cases/100,000 persons; during 2008–2010, incidence was calculated as the number of confirmed and probable cases/100,000 persons. US 2010 Census population estimates were used as the denominator for surveillance data incidence calculations.

Main Article

TOP